There are two aspects to that. From a cost perspective, as I've said, generics on average now are selling at something like 20% to 25% of the price of an equivalent brand-name product. If you delay for two years, you're paying an extra 75% to 80% on that product for an extra two years. That affects provincial drug program budgets; it affects employee plans; and it affects people who pay out of pocket, and those costs are very significant.
Second, it is very important that we have a strong generic industrial base. We manufacture products here. We sell, as I've said, to over 115 countries. It is critically important that we're able to get on the market when patents expire in Canada and around the world. One aspect of Bill C-30 we do support strongly is this ability to export during the extension period. That is very important. We are very supportive of that, and in our view, it's nicely drafted and should go forward.